Palliative care always

ONCOLOGY (United States)

Volumn 27, Issue 1, 2013, Pages

  Ramchandran, Kavitha ^a,b   Von Roenn, Jamie H ^c  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD CANCER INSTITUTE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; CRIZOTINIB; ERLOTINIB; GEFITINIB; LEUPRORELIN; PLATINUM DERIVATIVE;

BONE METASTASIS; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DIGITAL RECTAL EXAMINATION; DRUG RESPONSE; EVIDENCE BASED MEDICINE; FAMILY COUNSELING; GENE MUTATION; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HOME CARE; HOSPITAL CARE; HOT FLUSH; HUMAN; JOB SATISFACTION; KARNOFSKY PERFORMANCE STATUS; LUNG NON SMALL CELL CANCER; LYMPHADENOPATHY; MEDICAL EDUCATION; OUTCOME ASSESSMENT; OUTPATIENT CARE; PATIENT CARE; PRACTICE GUIDELINE; PROSTATE BIOPSY; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOCIAL PSYCHOLOGY; SOCIAL STIGMA; STANDARDIZATION; SURVIVAL TIME; TERMINAL CARE; TREND STUDY; WORLD HEALTH ORGANIZATION;

EID: 84874633053     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (111)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Seow H, Barbera L, Sutradhar R, et al. Trajectory of performance status and symptom scores for patients with cancer during the last six months of life. J Clin Oncol. 2011;29:1151-8.
3. Sepulveda C, Marlin A, Yoshida T, Ullrich A. Palliative Care: the World Health Organizations global perspective. J Pain Symptom Manage. 2002;24:91-6.
4. Center to Advance Palliative Care. Defining palliative care. Available from: http://www.capc.org/building-a-hospital-based-palliative-care-program/case/definingpc. Accessed December 17, 2012.
5. Junger S, Payne S, Brearley S, et al. Consensus building in palliative care: A Europe-wide delphi study on common understandings and conceptual differences. J Pain Symptom Manage. 2012;44:192-205.
6. Van Mechelen W, Aertgeerts B, De Ceulaer K, et al. Defining the palliative care patient: a systematic review. Palliat Med. 2012 Feb 6. [Epub ahead of print]
7. Clark D. From margins to centre: a review of the history of palliative care in cancer. Lancet Oncol. 2007;8:430-8.
8. McGrath PA. Development of the World Health Organization guidelines on cancer pain relief and palliative care in children. J Pain Symptom Manage. 1996;12:87-92.
9. Roszkowski K, Pluzanska A, Krzakowski M, et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer. 2000;27:145-57.
10. Gridelli C. The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study. Oncologist. 2001;6 Suppl 1:4-7.
11. Anderson H, Hopwood P, Stephens RJ, et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancera randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer. 2000;83:447-53.
12. Ranson M, Davidson N, Nicolson M, et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2000; 92:1074-80.
13. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095-103.
14. Ellis PA, Smith IE, Hardy JR, et al. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer. 1995;71:366-70.
15. Cullen MH, Billingham LJ, Woodroffe CM, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol. 1999;17:3188-94.
16. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 2008;26:4617-25.
17. Socinski MA, Morris DE, Masters GA, Lilenbaum R. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest. 2003;123:226S-43S.
18. Cullen M. Best supportive care has had its day. Lancet Oncol. 2001;2:173-5.
19. Medley L, Cullen M. Best supportive care versus palliative chemotherapy in non-small-cell lung cancer. Curr Opin Oncol. 2002;14:384-8.
20. Zafar SY, Currow DC, Cherny N, et al. Consensus-based standards for best supportive care in clinical trials in advanced cancer. Lancet Oncol. 2012;13:e77-82.
21. Currow DC, Foley K, Zafar SY, et al. The need for a re-evaluation of best supportive care studies reported to date. Br J Cancer. 2011;104:390-1.
22. Cherny NI, Abernethy AP, Strasser F, et al. Improving the methodologic and ethical validity of best supportive care studies in oncology: lessons from a systematic review. J Clin Oncol. 2009;27:5476-86.
23. Zafar SY, Currow D, Abernethy AP. Defining best supportive care. J Clin Oncol. 2008;26:5139-40.
24. Cella D, Herbst RS, Lynch TJ, et al. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol. 2005;23:2946-54.
25. Brown ER, Shepherd FA. Erlotinib in the treatment of non-small cell lung cancer. Expert Rev Anticancer Ther. 2005;5:767-75.
26. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-32.
27. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-57.
28. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 2003;21:2237-46.
29. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290:2149-58.
30. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693-703.
31. Antoniu SA. Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease? Evaluation of Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363(18):1693-703. Expert Opin Ther Targets. 2011;15:351-3.
32. Lee JK, Park HS, Kim DW, et al. Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced non-small-cell lung cancer. Cancer. 2012;118:3579-86.
33. Ramalingam SS, Khuri FR. Lung cancer with translocation in the anaplastic lymphoma kinase gene: a disease within a disease. Cancer. 2012;118:4370-1.
34. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363:733-42.
35. Jacobsen J, Jackson V, Dahlin C, et al. Components of early outpatient palliative care consultation in patients with metastatic nonsmall cell lung cancer. J Palliat Med. 2011;14:459-64.
36. Temel JS, Greer JA, Admane S, et al. Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care. J Clin Oncol. 2011;29:2319-26.
37. Bakitas M, Lyons KD, Hegel MT, et al. Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. JAMA. 2009;302:741-9.
38. Jordhoy MS, Fayers P, Saltnes T, et al. A palliative-care intervention and death at home: a cluster randomised trial. Lancet. 2000;356:888-93.
39. Jordhoy MS, Fayers P, Loge JH, et al. Quality of life in palliative cancer care: results from a cluster randomized trial. J Clin Oncol. 2001;19:3884-94.
40. Follwell M, Burman D, Le LW, et al. Phase II study of an outpatient palliative care intervention in patients with metastatic cancer. J Clin Oncol. 2009;27:206-13.
41. Strasser F, Sweeney C, Willey J, et al. Impact of a half-day multidisciplinary symptom control and palliative care outpatient clinic in a comprehensive cancer center on recommendations, symptom intensity, and patient satisfaction: a retrospective descriptive study. J Pain Symptom Manage. 2004;27:481-91.
42. Casarett DJ, Hirschman KB, Coffey JF, Pierre L. Does a palliative care clinic have a role in improving end-of-life care? Results of a pilot program. J Palliat Med. 2002;5:387-96.
43. Peppercorn JM, Smith TJ, Helft PR, et al. American society of clinical oncology statement: toward individualized care for patients with advanced cancer. J Clin Oncol. 2011;29:755-60.
44. ASCO-ESMO consensus statement on quality cancer care. Ann Oncol. 2006;17:1063-4.
45. McNiff KK, Neuss MN, Jacobson JO, et al. Measuring supportive care in medical oncology practice: lessons learned from the quality oncology practice initiative. J Clin Oncol. 2008;26:3832-7.
46. Smith TJ, Temin S, Alesi ER, et al. American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care. J Clin Oncol. 2012;30:880-7.
47. Schnipper LE, Smith TJ, Raghavan D, et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol. 2012; 30:1715-24.
48. Levy MH, Back A, Benedetti C, et al. NCCN clinical practice guidelines in oncology: palliative care. J Natl Compr Canc Netw. 2009;7:436-73.
49. Glare PA, Semple D, Stabler SM, Saltz LB. Palliative care in the outpatient oncology setting: evaluation of a practical set of referral criteria. J Oncol Pract. 2011;7:366-70.
50. Reuben DB, Mor V, Hiris J. Clinical symptoms and length of survival in patients with terminal cancer. Arch Intern Med. 1988;148:1586-91.
51. Morita T, Tsunoda J, Inoue S, Chihara S. Validity of the palliative performance scale from a survival perspective. J Pain Symptom Manage. 1999;18:2-3.
52. Evans C, McCarthy M. Prognostic uncertainty in terminal care: can the Karnofsky index help? Lancet. 1985;1:1204-6.
53. Maltoni M, Nanni O, Derni S, et al. Clinical prediction of survival is more accurate than the Karnofsky performance status in estimating life span of terminally ill cancer patients. Eur J Cancer. 1994;30A:764-6.
54. Maltoni M, Pirovano M, Scarpi E, et al. Prediction of survival of patients terminally ill with cancer. Results of an Italian prospective multicentric study. Cancer. 1995;75:2613-22.
55. Goudas LC, Bloch R, Gialeli-Goudas M, et al. The epidemiology of cancer pain. Cancer Invest. 2005;23:182-90.
56. Ripamonti C. Management of dyspnea in advanced cancer patients. Support Care Cancer. 1999;7:233-43.
57. Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol. 1997;34:4-12.
58. Lawrence DP, Kupelnick B, Miller K, et al. Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients. J Natl Cancer Inst Monogr. 2004;40-50.
59. Fauci J, Schneider K, Walters C, et al. The utilization of palliative care in gynecologic oncology patients near the end of life. Gynecol Oncol. 2012;127:175-9.
60. Webster J. PS1-20: Hospice use in metastatic colorectal cancer patients. Clin Med Res. 2012;10:149.
61. Akashi M, Yano E, Aruga E. Under-diagnosis of pain by primary physicians and late referral to a palliative care team. BMC Palliat Care. 2012;11:7.
62. Dalal S, Palla S, Hui D, et al. Association between a name change from palliative to supportive care and the timing of patient referrals at a comprehensive cancer center. Oncologist. 2011;16:105-11.
63. Fukui S, Fujita J, Tsujimura M, et al. Late referrals to home palliative care service affecting death at home in advanced cancer patients in Japan: a nationwide survey. Ann Oncol. 2011;22:2113-20.
64. National Hospice and Palliative Care Organization (NHPCO). NHPCO facts and figures: hospice care in America. 2011 ed. Available from: http://www.nhpco.org/files/public/statistics_research/2011_facts_figures.pdf. Accessed December 17, 2012.
65. von Gunten CF, Lupu D. Recognizing palliative medicine as a subspecialty: what does it mean for oncology? J Support Oncol. 2004;2:166-74.
66. Clark D. The development of palliative medicine in the UK and Ireland. In: Bruera E, Higginson IJ, Ripamonti R, von Gunten C (editors). Textbook of palliative medicine. London: Hodder Arnold, 2006;3-11.
67. Muir JC, Daly F, Davis MS, et al. Integrating palliative care into the outpatient, private practice oncology setting. J Pain Symptom Manage. 2010;40:126-35.
68. Dudgeon D, King S, Howell D, et al. Cancer Care Ontarios experience with implementation of routine physical and psychological symptom distress screening. Psychooncology. 2012;21:357-64.
69. Morrison RS, Augustin R, Souvanna P, Meier DE. Americas care of serious illness: a state-by-state report card on access to palliative care in our nations hospitals. J Palliat Med. 2011;14:1094-6.
70. Grant M, Elk R, Ferrell B, et al. Current status of palliative careclinical implementation, education, and research. CA Cancer J Clin. 2009;59:327-35.
71. Hui D, Elsayem A, De la Cruz M, et al. Availability and integration of palliative care at US cancer centers. JAMA. 2010;303:1054-61.
72. Meier DE, Beresford L. Outpatient clinics are a new frontier for palliative care. J Palliat Med. 2008;11:823-8.
73. Ferris FD, Bruera E, Cherny N, et al. Palliative cancer care a decade later: accomplishments, the need, next stepsfrom the American Society of Clinical Oncology. J Clin Oncol. 2009;27:3052-8.
74. von Gunten CF. Arrogance ignorance paradox. J Palliat Med. 2005;8:898-9.
75. Portenoy RK. Treatment of cancer pain. Lancet. 2011;377:2236-47.
76. Breuer B, Fleishman SB, Cruciani RA, Portenoy RK. Medical oncologists attitudes and practice in cancer pain management: a national survey. J Clin Oncol. 2011;29:4769-75.
77. Von Roenn JH, Cleeland CS, Gonin R, et al. Physician attitudes and practice in cancer pain management. A survey from the Eastern Cooperative Oncology Group. Ann Intern Med. 1993;119:121-6.
78. Buss MK, Lessen DS, Sullivan AM, et al. Hematology/oncology fellows training in palliative care: results of a national survey. Cancer. 2011;117:4304-11.
79. Buss MK, Lessen DS, Sullivan AM, et al. A study of oncology fellows training in end-of-life care. J Support Oncol. 2007;5:237-42.
80. Ferrell B, Connor SR, Cordes A, et al. The national agenda for quality palliative care: the National Consensus Project and the National Quality Forum. J Pain Symptom Manage. 2007;33:737-44.
81. Altilio T, Otis-Green S, Dahlin CM. Applying the National Quality Forum Preferred Practices for Palliative and Hospice Care: a social work perspective. J Soc Work End Life Palliat Care. 2008;4:3-16.
82. National Consensus Project for Quality Palliative Care: Clinical Practice Guidelines for quality palliative care, executive summary. J Palliat Med. 2004;7:611-27.
83. Colby WH, Dahlin C, Lantos J, et al. The National Consensus Project for Quality Palliative Care Clinical Practice Guidelines Domain 8: ethical and legal aspects of care. HEC Forum. 2010;22:117-31.
84. American Board of Internal Medicine. Medical oncology certification examination blueprint. Available from: http://www.abim.org/pdf/blueprint/medon_cert.pdf. Accessed December 17, 2012.
85. Davies B, Sehring SA, Partridge JC, et al. Barriers to palliative care for children: perceptions of pediatric health care providers. Pediatrics. 2008;121:282-8.
86. Enguidanos S, Housen P, Goldstein R, et al. Physician and nurse perceptions of a new inpatient palliative care consultation project: implications for education and training. J Palliat Med. 2009;12:1137-42.
87. Fadul N, Elsayem A, Palmer JL, et al. Supportive versus palliative care: whats in a name?: a survey of medical oncologists and midlevel providers at a comprehensive cancer center. Cancer. 2009;115:2013-21.
88. Keating NL, Landrum MB, Rogers SO, Jr., et al. Physician factors associated with discussions about end-of-life care. Cancer. 2010;116:998-1006.
89. Wright AA, Zhang B, Ray A, et al. Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. JAMA. 2008;300:1665-73.
90. Smith TJ, Dow LA, Virago E, et al. Giving honest information to patients with advanced cancer maintains hope. Oncology (Williston Park). 2010;24:521-5.
91. Smith TJ, Dow LA, Virago EA, et al. A pilot trial of decision aids to give truthful prognostic and treatment information to chemotherapy patients with advanced cancer. J Support Oncol. 2011;9:79-86.
92. Innes S, Payne S. Advanced cancer patients prognostic information preferences: a review. Palliat Med. 2009;23:29-39.
93. Gordon EJ, Daugherty CK. Hitting you over the head: oncologists disclosure of prognosis to advanced cancer patients. Bioethics. 2003;17:142-68.
94. Penson RT, Green KM, Chabner BA, Lynch TJ, Jr. When does the responsibility of our care end: bereavement. Oncologist. 2002;7:251-8.
95. Bruera E, Russell N, Sweeney C, et al. Place of death and its predictors for local patients registered at a comprehensive cancer center. J Clin Oncol. 2002;20:2127-33.
96. Higginson IJ, Astin P, Dolan S. Where do cancer patients die? Ten-year trends in the place of death of cancer patients in England. Palliat Med. 1998;12:353-63.
97. Higginson IJ, Sen-Gupta GJ. Place of care in advanced cancer: a qualitative systematic literature review of patient preferences. J Palliat Med. 2000;3:287-300.
98. Townsend J, Frank AO, Fermont D, et al. Terminal cancer care and patients preference for place of death: a prospective study. BMJ. 1990;301:415-7.
99. Sharma G, Freeman J, Zhang D, Goodwin JS. Trends in end-of-life ICU use among older adults with advanced lung cancer. Chest. 2008;133:72-8.
100. Earle CC, Neville BA, Landrum MB, et al. Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol. 2004;22:315-21.
101. Reinhardt UE. Fees, volume and spending at Medicare. 24 December 2010. Available from: http://economix.blogs.nytimes.com/2010/12/24/fees-volume-and-spending-at-medicare.
102. Schroeder SA. Personal reflections on the high cost of American medical care: many causes but few politically sustainable solutions. Arch Intern Med. 2011;171:722-7.
103. Kelley AS, McGarry K, Fahle S, et al. Out-of-pocket spending in the last five years of life. J Gen Intern Med. 2012 Sep 5. [Epub ahead of print]
104. Hoch JS. Improving efficiency and value in palliative care with net benefit regression: an introduction to a simple method for cost-effectiveness analysis with person-level data. J Pain Symptom Manage. 2009;38:54-61.
105. Brumley R, Enguidanos S, Jamison P, et al. Increased satisfaction with care and lower costs: results of a randomized trial of in-home palliative care. J Am Geriatr Soc. 2007;55:993-1000.
106. Gade G, Venohr I, Conner D, et al. Impact of an inpatient palliative care team: a randomized control trial. J Palliat Med. 2008;11:180-90.
107. Naik G. Unlikely way to cut hospital costs: comfort the dying. Palliative-care unit offers painkillers and support; fewer tests, treatments. Wall St J (East Ed). 2004;A1, A12.
108. Morrison RS, Penrod JD, Cassel JB, et al. Cost savings associated with US hospital palliative care consultation programs. Arch Intern Med. 2008; 168:1783-90.
109. Smith TJ, Cassel JB. Cost and non-clinical outcomes of palliative care. J Pain Symptom Manage. 2009;38:32-44.
110. Neubauer MA, Hoverman JR, Kolodziej M, et al. Cost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community setting. J Oncol Pract. 2010;6:12-8.
111. Smith TJ et al. American Society of Clinical Oncology Provisional Clinical Opinion: the integration of palliative care into standard oncology care. J Clin Oncol. 2012;30:880-7.